Structure-activity studies on the oxytocin antagonist 1 (L-371,257; K-i = 9
.3 nM) have led to the identification of a related series of compounds cont
aining an ortho-trifluoroethoxyphenylacetyl core which are orally bioavaila
ble and have significantly improved potency in vitro and in vivo, e.g., com
pound 8 (L-374,943; K-i = 1.4 nM), (C) 1999 Elsevier Science Ltd. All right
s reserved.